C. Reed

发表

The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder

M. Thase, M. Athanasiou, C. Reed, 2012, Current medical research and opinion.

The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive Disorder.

M. Liebowitz, M. Athanasiou, C. Reed, 2011, Psychopharmacology bulletin.

Prevalence of early-onset atrial fibrillation in congenital long QT syndrome.

Michael J Ackerman, C. Reed, D. Tester, 2008, Heart rhythm.

Pharmacogenetic Issues in Thorough QT Trials

R. Judson, C. Reed, B. Salisbury, 2012, Molecular Diagnosis & Therapy.

The Role of Pharmacogenetics in Treating Central Nervous System Disorders

M. Athanasiou, C. Reed, M. Patnaik, 2008, Experimental biology and medicine.

Discovery of Genetic Markers Associated with Clozapine Induced Agranulocytosis.

A. Malhotra, M. Athanasiou, J. Kane, 2005 .

Yeast amber suppressors corresponding to tRNA3Leu genes.

C. Reed, J. Stewart, F. Sherman, 1984, Journal of molecular biology.

Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia

R Kucherlapati, A. Malhotra, R. Kucherlapati, 2007, Molecular Psychiatry.

Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis.

A. Malhotra, M. Athanasiou, T. Lencz, 2011, The Journal of clinical psychiatry.

New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals.

A. Windemuth, R. Judson, G. Ruaño, 2004, Atherosclerosis.

The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

G. Ginsburg, D. Voora, C. Reed, 2009, Journal of the American College of Cardiology.

The effect of vilazodone on sexual function during the treatment of major depressive disorder.

S. Kennedy, C. Reed, S. Gallipoli, 2013, The journal of sexual medicine.

A 1-Year, Open-Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder

C. Reed, D. Kajdasz, Heidi Whalen, 2011, Journal of clinical psychopharmacology.

Pharmacogenetic Predictors of Statin-Mediated Low-Density Lipoprotein Cholesterol Reduction and Dose Response

G. Ginsburg, D. Voora, C. Reed, 2008, Circulation. Cardiovascular genetics.

Vilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depression.

M. Athanasiou, C. Reed, K. Rickels, 2009, Personalized medicine.

A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.

M. Athanasiou, C. Reed, D. Kajdasz, 2011, The Journal of clinical psychiatry.

Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.

M. Athanasiou, C. Reed, Heidi Whalen, 2009, The Journal of clinical psychiatry.

‘Insulin autoantibody affinity measurement using a single concentration of unlabelled insulin competitor discriminates risk in relatives of patients with type 1 diabetes

P. Bingley, C. Reed, A. Williams, 2012, Clinical and experimental immunology.

The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder

M. Thase, M. Athanasiou, C. Reed, 2012, Current medical research and opinion.

Restoring value to stalled Phase II compounds: the case for developing a novel compound for depression using pharmacogenetics.

R. Judson, M. Athanasiou, C. Reed, 2005, Pharmacogenomics.

Pharmacogenetic Predictors of Statin-Mediated Low-Density Lipoprotein Cholesterol Reduction and Dose Response

G. Ginsburg, D. Voora, C. Reed, 2008, Circulation. Cardiovascular genetics.